HudsonAlpha Welcomes New Vice President for Translational Health Science, Jennifer Lovejoy
Lovejoy will lead HOPE‑AD and related multi‑omic, longitudinal, and intervention-based programs focused on chronic‑disease prevention and precision health.
The HudsonAlpha Institute for Biotechnology recently welcomed Jennifer Lovejoy, PhD, as its new Vice President for Translational Health Science.
Lovejoy brings over three decades of experience in personalized lifestyle medicine, behavioral science, obesity, and healthy aging, most recently serving as the Chief Translational Science Officer of Phenome Health. Throughout her career, Lovejoy has specialized in bridging the gap between scientific discovery, clinical operations, and community health interventions.
In her new role, Dr. Lovejoy will lead HudsonAlpha’s programs that connect complex biological science, like genetics and molecular data, with daily lifestyle habits to prevent chronic disease and tailor personalized health plans.
We are thrilled to welcome Dr. Lovejoy to HudsonAlpha. Her extensive leadership background in precision health and translational science makes her the ideal leader to guide our multi-omic intervention programs, working alongside our research and clinical teams. Jennifer’s unique ability to connect advanced genomic research with real-world lifestyle interventions will be instrumental as we scale our public health initiatives across Alabama and beyond.
Prior to joining HudsonAlpha, Lovejoy served as an integral collaborator on the Healthy Outcomes Through Phenomic Exploration for Alzheimer’s Disease (HOPE-AD) initiative team while at Phenome Health, working closely with HudsonAlpha scientists and genetic counselors to launch and successfully complete the initial pilot project.
The HOPE-AD pilot project enrolled 159 individuals with a family history of Alzheimer’s disease or other dementias, but with no cognitive decline themselves. Of those, 52 individuals were identified as at high risk for dementia and were invited to participate in the full pilot study. During the study, participants received personalized lifestyle intervention coaching, including access to a nutritionist, behavioral support, and “brain training” through an online app.
Participants were evaluated over six months, tracking cognitive function, overall health metrics (such as blood pressure and metabolic markers), and levels of the Alzheimer’s disease biomarker p-tau-217. Preliminary results indicate that participants sustained healthy habits over the six-month period, promoting long-term lifestyle changes such as improved diets and regular exercise. Notably, participants who adhered more closely to the lifestyle modifications had a smaller decline in cognitive scores over the study period. Additionally, over 85 percent of participants reacted positively to receiving actionable data regarding their potential future health risks.
Building on the success of the pilot project, Lovejoy will play a critical role in moving HOPE-AD from a localized pilot to a statewide project. Under her operational leadership, the program plans to expand participant reach and streamline remote data collection by introducing at-home testing kits and scaling cross-disciplinary clinical collaborations.
Joining HudsonAlpha at such a pivotal moment for translational science is an extraordinary opportunity. The HOPE-AD pilot has already demonstrated the powerful intersection of multi-omic research and targeted lifestyle intervention. I look forward to leading this talented multidisciplinary team as we scale these programs statewide, empowering individuals with precision health tools to proactively combat cognitive decline and chronic disease.
